Is Insmed (INSM) The Best Healthcare Stock to Buy Now?

10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. Insmed (NASDAQ:INSM) ranks #2 (see 5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller).

Insmed (NASDAQ:INSM) makes treatments for serious lung diseases caused by chronic inflammation or infection. Its core products are Brinsupri (brensocatib) and Arikayce.

In 2025, Brinsupri generated about $144.6 million in Q4 sales, bringing full-year revenue to roughly $600+ million, reflecting very strong early launch growth. This represents around 67% year-over-year growth. For 2026, Insmed expects Brinsupri to hit about $1 billion in annual sales, driven by broader patient adoption.

Arikayce in 2025 generated about $433.8 million in full-year sales, up 19% year over year, and the company guided 2026 sales of $450–$470 million.

Insmed’s (NASDAQ:INSM) pipeline is also strong. One key candidate is TPIP (treprostinil inhalation powder), a treatment being developed for PAH (pulmonary arterial hypertension) and PH-ILD (pulmonary hypertension associated with interstitial lung disease). Some estimates suggest the product can potentially generate over $4 billion in peak annual sales.

Artisan Small Cap Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its fourth quarter 2025 investor letter:

“Our top contributors in Q4 were MACOM Technology Solutions, Insmed Incorporated (NASDAQ:INSM) and Vita Coco. Insmed is a biotechnology company focused on pulmonary diseases. We exited our position during the quarter due to market cap considerations, though the stock remained a top performer. Its strength was driven by the successful launch of Brinsupri™ (brensocatib), the first approved therapy for non-cystic fibrosis bronchiectasis, which generated $28 million in initial sales from roughly 2,500 patients and 1,700 prescribers, along with a robust pipeline of additional potential therapies (Click Here to Read the Letter in Detail).”

While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.